CA2726894A1 - Therapeutic agents comprising elastin-like peptides - Google Patents

Therapeutic agents comprising elastin-like peptides Download PDF

Info

Publication number
CA2726894A1
CA2726894A1 CA2726894A CA2726894A CA2726894A1 CA 2726894 A1 CA2726894 A1 CA 2726894A1 CA 2726894 A CA2726894 A CA 2726894A CA 2726894 A CA2726894 A CA 2726894A CA 2726894 A1 CA2726894 A1 CA 2726894A1
Authority
CA
Canada
Prior art keywords
therapeutic agent
component
elp
glp
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2726894A
Other languages
English (en)
French (fr)
Inventor
Ashutosh Chilkoti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Priority to CA2953975A priority Critical patent/CA2953975C/en
Publication of CA2726894A1 publication Critical patent/CA2726894A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2726894A 2008-06-27 2009-06-29 Therapeutic agents comprising elastin-like peptides Abandoned CA2726894A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2953975A CA2953975C (en) 2008-06-27 2009-06-29 Therapeutic agents comprising elastin-like peptides

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7622108P 2008-06-27 2008-06-27
US61/076,221 2008-06-27
PCT/US2009/049059 WO2009158704A2 (en) 2008-06-27 2009-06-29 Therapeutic agents comprising elastin-like peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2953975A Division CA2953975C (en) 2008-06-27 2009-06-29 Therapeutic agents comprising elastin-like peptides

Publications (1)

Publication Number Publication Date
CA2726894A1 true CA2726894A1 (en) 2009-12-30

Family

ID=41445383

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2726894A Abandoned CA2726894A1 (en) 2008-06-27 2009-06-29 Therapeutic agents comprising elastin-like peptides
CA2953975A Active CA2953975C (en) 2008-06-27 2009-06-29 Therapeutic agents comprising elastin-like peptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2953975A Active CA2953975C (en) 2008-06-27 2009-06-29 Therapeutic agents comprising elastin-like peptides

Country Status (7)

Country Link
US (9) US8178495B2 (enExample)
EP (4) EP2307038A4 (enExample)
JP (4) JP2011526303A (enExample)
CN (2) CN102131516B (enExample)
CA (2) CA2726894A1 (enExample)
HK (1) HK1215182A1 (enExample)
WO (1) WO2009158704A2 (enExample)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2616701C (en) * 2005-07-28 2018-10-02 Global Research Technologies, Llc Removal of carbon dioxide from air
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20130172274A1 (en) * 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
EP1971355B1 (en) 2005-12-20 2020-03-11 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
JP2011526303A (ja) 2008-06-27 2011-10-06 デューク ユニバーシティ エラスチン様ペプチドを含む治療剤
HUE068164T2 (hu) 2008-10-17 2024-12-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
AU2010258898B8 (en) 2009-06-08 2015-02-05 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
MX366935B (es) 2009-08-14 2019-07-31 Phasebio Pharmaceuticals Inc Peptidos intestinales vasoactivos modificados.
CA2780460C (en) 2009-11-13 2018-09-04 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
WO2011152694A2 (en) * 2010-06-04 2011-12-08 Sk Chemicals Co., Ltd. Fusion protein having factor vii activity
RS55378B1 (sr) 2010-08-30 2017-03-31 Sanofi Aventis Deutschland Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
US9671410B2 (en) 2011-01-16 2017-06-06 The Procter & Gamble Company Biomarker-based methods for identifying and formulating compositions that improve skin quality and reduce the visible signs of aging in skin
CA2827170A1 (en) 2011-02-11 2012-08-16 David M. Hilbert Monovalent and multivalent multispecific complexes and uses thereof
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9561262B2 (en) 2011-06-06 2017-02-07 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
US20130090285A1 (en) * 2011-06-27 2013-04-11 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
CA2846209C (en) * 2011-08-24 2022-04-05 Phasebio Pharmaceuticals, Inc. Systemic sustained release formulation comprising elastin­like peptide repeating sequence and protein active agent
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
SG11201402661TA (en) * 2011-11-28 2014-08-28 Phasebio Pharmaceuticals Inc Therapeutic agents comprising insulin amino acid sequences
US9200305B2 (en) 2011-12-20 2015-12-01 Bio-Rad Laboratories, Inc. Generation of engineered molecular weight standards
US20150005233A1 (en) * 2012-02-08 2015-01-01 Seneb Biosciences, Inc. Treatment of hypoglycemia
CN107496932A (zh) 2012-02-27 2017-12-22 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
CN108524919A (zh) 2012-05-17 2018-09-14 延伸生物科学股份有限公司 用于改进的药物递送的载体
US10253089B2 (en) 2012-05-30 2019-04-09 University Of Utah Research Foundation Matrix metalloproteinase cleavable protein polymers for cancer gene therapy
WO2014028776A1 (en) * 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
US20150290328A1 (en) 2012-11-20 2015-10-15 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
PT2934568T (pt) 2012-12-21 2018-01-04 Sanofi Sa Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina
EP2945643A4 (en) * 2013-01-15 2017-04-26 Phasebio Pharmaceuticals, Inc. Therapeutic agents, compositions, and methods for glycemic control
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
WO2015051001A2 (en) * 2013-10-01 2015-04-09 University Of Mississippi Medical Center Composition and method for therapeutic agent delivery during pregnancy
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
WO2015168321A2 (en) * 2014-04-29 2015-11-05 University Of Mississippi Medical Center Ocular compositions and methods thereof
PL3139948T3 (pl) * 2014-05-07 2020-08-10 Novo Nordisk A/S Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21
EP3139949B1 (en) 2014-05-08 2020-07-29 Phasebio Pharmaceuticals, Inc. Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2016005903A2 (en) * 2014-07-08 2016-01-14 Theramyt Novobiologics Private Limited A process for obtaining exendin-4
JP6657230B2 (ja) * 2014-09-24 2020-03-04 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション インクレチン−インスリンコンジュゲート
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2016077325A1 (en) 2014-11-10 2016-05-19 The Procter & Gamble Company Personal care compositions with two benefit phases
US10966916B2 (en) 2014-11-10 2021-04-06 The Procter And Gamble Company Personal care compositions
EP3217949B1 (en) 2014-11-10 2020-06-17 The Procter and Gamble Company Personal care compositions with two benefit phases
WO2016077618A1 (en) * 2014-11-12 2016-05-19 University Of Mississippi Medical Center Kidney-targeted drug delivery systems
JP7075757B2 (ja) * 2014-11-21 2022-05-26 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 制御放出および持続的放出のためのｅｌｐ融合タンパク質
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
WO2016130518A2 (en) 2015-02-09 2016-08-18 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US10385115B2 (en) 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
CN104894196A (zh) * 2015-05-28 2015-09-09 中国药科大学 一种制备重组艾塞那肽或其衍生物的新方法
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
JP6882782B2 (ja) 2015-08-04 2021-06-02 デューク ユニバーシティ 遺伝子コードされた本質的に無秩序な送達用ステルスポリマーおよびその使用方法
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
DE102016103843A1 (de) 2016-03-03 2017-09-07 Biotronik Ag Reduktion von paravalvulärer Leckage durch kontrollierten Thrombusaufbau
US10662236B2 (en) * 2016-04-07 2020-05-26 Industry-University Cooperation Foundation Hanyang University Erica Campus Vascular endothelial growth factor receptor targeting peptide-elastin fusion polypeptides
KR102449167B1 (ko) * 2016-05-06 2022-09-28 파세비오 파마수티컬스 인코포레이티드 제어된 지속 방출을 위한 elp 융합 단백질
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
CN107778361B (zh) * 2016-08-30 2021-07-09 上海交通大学 多肽hl-39及其制备与应用
WO2018045872A1 (zh) * 2016-09-06 2018-03-15 中国药科大学 一种多肽及其用途
US11135301B2 (en) 2016-09-14 2021-10-05 Duke University Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
US11337994B2 (en) 2016-09-15 2022-05-24 University Of Utah Research Foundation In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
JP2020500150A (ja) 2016-09-23 2020-01-09 デューク ユニバーシティ 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド
CN106519040B (zh) * 2016-11-02 2020-03-27 南京大学 一种含肿瘤坏死因子相关凋亡诱导配体的融合蛋白和其制备方法及由该蛋白自组装的纳米粒
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
US10849914B2 (en) 2017-06-12 2020-12-01 University Of Utah Research Foundation Methods for producing chemoembolic agents for the delivery of anti-cancer agents
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
US11173212B2 (en) 2017-09-28 2021-11-16 Indian Institute Of Science Education And Research Supramolecular protein assemblies with advanced functions and synthesis thereof
EP3697374B1 (en) 2017-10-20 2022-02-16 The Procter & Gamble Company Aerosol foam skin cleanser
CN111212625B (zh) 2017-10-20 2023-05-23 宝洁公司 气溶胶泡沫洁肤剂
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
EP3788343B1 (en) 2018-04-30 2024-03-27 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
WO2020028806A1 (en) * 2018-08-02 2020-02-06 Duke University Dual agonist fusion proteins
WO2020051541A1 (en) * 2018-09-07 2020-03-12 Duke University Nanoparticulate drug delivery systems
WO2020112486A1 (en) 2018-11-29 2020-06-04 The Procter & Gamble Company Methods for screening personal care products
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
US11513254B2 (en) 2019-01-10 2022-11-29 Baker Hughes Oilfield Operations Llc Estimation of fracture properties based on borehole fluid data, acoustic shear wave imaging and well bore imaging
JP7777451B2 (ja) * 2019-04-12 2025-11-28 ジェルター， インコーポレイテッド 組換えエラスチンおよびその産生
CN111939244B (zh) * 2019-05-14 2024-08-06 阿莫生命科学有限公司 用于预防或治疗糖尿病并发症的药物组合物
CN110101868B (zh) * 2019-05-24 2021-03-23 北京大学 一种环境刺激响应性蛋白质高分子偶联物自组装体及其制备方法与应用
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
CN113735977A (zh) * 2020-05-28 2021-12-03 江苏康缘瑞翱生物医药科技有限公司 rhFGF21融合蛋白、编码其的多核苷酸、包含其组合物及其用途
JP2025534350A (ja) 2022-09-30 2025-10-15 エクステンド バイオサイエンシズ インコーポレーテッド 長時間作用型副甲状腺ホルモン
WO2025076213A1 (en) * 2023-10-04 2025-04-10 The Board Of Trustees Of The Leland Stanford Junior University Isothermally phase-separable elastin-like polypeptides, compositions, and methods of use thereof
CN117398525B (zh) * 2023-12-05 2024-03-12 北京大学人民医院 表达Exendin-4蛋白的间充质干细胞及其用途

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4187852A (en) 1976-07-09 1980-02-12 The University Of Alabama Synthetic elastomeric insoluble cross-linked polypentapeptide
US4132746A (en) 1976-07-09 1979-01-02 University Of Alabama, Birmingham Medical & Education Foundation Synthetic elastomeric insoluble cross-linked polypentapeptide
DE2923787A1 (de) * 1979-06-12 1980-12-18 Max Planck Gesellschaft Verfahren zur selektiven bildung von disulfidbruecken in polypeptiden und die dabei erhaltenen produkte als wirkstoffe enthaltende arzneimittel
US4500700A (en) 1981-10-02 1985-02-19 The Board Of Trustees Of The University Of Alabama For The University Of Alabama In Birmingham Elastomeric composite material comprising a polypentapeptide having an amino acid of opposite chirality in position three
US4474851A (en) * 1981-10-02 1984-10-02 The University Of Alabama In Birmingham Elastomeric composite material comprising a polypeptide
US4589882A (en) 1983-09-19 1986-05-20 Urry Dan W Enzymatically crosslinked bioelastomers
US4752638A (en) 1983-11-10 1988-06-21 Genetic Systems Corporation Synthesis and use of polymers containing integral binding-pair members
US4749647A (en) 1984-06-22 1988-06-07 Genetic Systems Corporation Polymerization-induced separation assay using recognition pairs
US4605641A (en) 1984-10-09 1986-08-12 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US4780409A (en) 1985-05-02 1988-10-25 Genetic Systems Corporation Thermally induced phase separation immunoassay
US4783523A (en) * 1986-08-27 1988-11-08 Urry Dan W Temperature correlated force and structure development of elastin polytetrapeptides and polypentapeptides
US4870055A (en) * 1986-04-17 1989-09-26 University Of Alabama At Birmingham Segmented polypeptide bioelastomers to modulate elastic modulus
US7138486B2 (en) * 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4898926A (en) * 1987-06-15 1990-02-06 The University Of Alabama At Birmingham/Research Foundation Bioelastomer containing tetra/penta-peptide units
US5770697A (en) * 1986-11-04 1998-06-23 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5243038A (en) * 1986-11-04 1993-09-07 Protein Polymer Technologies, Inc. Construction of synthetic DNA and its use in large polypeptide synthesis
US5496712A (en) * 1990-11-06 1996-03-05 Protein Polymer High molecular weight collagen-like protein polymers
US5830713A (en) * 1986-11-04 1998-11-03 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US5514581A (en) * 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US6184348B1 (en) * 1986-11-04 2001-02-06 Protein Polymer Technologies Functional recombinantly prepared synthetic protein polymer
US6018030A (en) * 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5773249A (en) * 1986-11-04 1998-06-30 Protein Polymer Technologies, Inc. High molecular weight collagen-like protein polymers
US5641648A (en) * 1986-11-04 1997-06-24 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US5606019A (en) * 1987-10-29 1997-02-25 Protien Polymer Technologies, Inc. Synthetic protein as implantables
IL87055A (en) 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
US5137711A (en) 1988-07-19 1992-08-11 Mallickrodt Medical, Inc. Paramagnetic dtpa and edta alkoxyalkylamide complexes as mri agents
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5234907A (en) 1989-06-30 1993-08-10 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US5236904A (en) 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
US5447912A (en) 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
ATE114458T1 (de) * 1990-03-27 1994-12-15 Bioelastics Res Ltd Bioelastomeres arzneimittelabgabesystem.
JPH07108232B2 (ja) 1990-10-09 1995-11-22 エム・ディ・リサーチ株式会社 ペプチド又は蛋白質の製造方法
US5235041A (en) * 1990-12-28 1993-08-10 Protein Polymer Technologies, Inc. Purification of structurally ordered recombinant protein polymers
US5646016A (en) * 1991-02-06 1997-07-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin, thioredoxin-like molecules, and modified thioredoxin-like molecules
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5393602A (en) 1991-04-19 1995-02-28 Bioelastics Research Ltd. Superabsorbent materials and uses thereof
US5958881A (en) 1991-04-25 1999-09-28 Korman; Louis Y. Composition containing VIP for injection and a method of enhancing visualization of tissues during medical procedures
IL99924A (en) 1991-10-31 1995-12-31 Yeda Res & Dev Derivatives of structurally modified vip and pharmaceutical compositions containing them
US5681816A (en) 1992-04-24 1997-10-28 Korman; Louis Y. Method of inducing temporary paralysis of the gastrointestinal tract during medical procedure
JP2575298B2 (ja) 1992-06-15 1997-01-22 フアイザー・インコーポレイテツド グルカゴン様ペプチド及びインシュリノトロピン誘導体
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5972883A (en) 1993-03-16 1999-10-26 Yeda Research And Development Co. Ltd. Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
DK38293D0 (da) 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
US5545617A (en) 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
CA2137206A1 (en) 1993-12-09 1995-06-10 John A. Galloway Glucagon-like insulinotropic peptides, compositions and methods
US5900405A (en) * 1994-01-24 1999-05-04 Bioelastics Research, Ltd. Polymers responsive to electrical energy
JPH10502333A (ja) 1994-04-07 1998-03-03 プロティーンニックス カンパニー バソアクティブ・インテスティナル・ポリペプチド
US5527610A (en) * 1994-05-20 1996-06-18 The Uab Research Foundation Elastomeric polypeptide matrices for preventing adhesion of biological materials
EP0776367B8 (en) 1994-08-09 2003-12-03 The Regents Of The University Of Minnesota Dna encoding turkey hypothalamic vasoactive intestinal peptide
US5854387A (en) * 1995-04-14 1998-12-29 Bioelastics Research, Ltd. Simple method for the purification of a bioelastic polymer
US5972406A (en) * 1995-04-14 1999-10-26 Bioelastics Research Ltd. Bioelastomers suitable as food product additives
US6004782A (en) * 1995-04-14 1999-12-21 Bioelastics Research Ltd. Hyperexpression of bioelastic polypeptides
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US6037321A (en) 1995-05-03 2000-03-14 Biostar Inc. Fusion proteins comprising vasoactive intestinal peptide or PACAP
EP0851768B1 (en) * 1995-09-01 2002-04-24 University of Washington Interactive molecular conjugates
DE851925T1 (de) 1995-09-21 2003-08-14 Genentech Inc., San Francisco Varianten des menschlichen wachstumshormons
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
DE69721548T2 (de) 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
US6063061A (en) 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
US5816259A (en) 1997-01-13 1998-10-06 Rose; Samuel Method for the diagnosis and treatment of cancer by the accumulation of radioactive precipitates in targeted cells
FI103540B (fi) 1997-04-28 1999-07-15 Nokia Mobile Phones Ltd Menetelmä pakettikytkentäisen datan siirtoon matkapuhelinjärjestelmäss ä
GB9718463D0 (en) 1997-08-29 1997-11-05 Dynal As Biomolecules
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
KR100627590B1 (ko) 1998-01-30 2006-09-25 다이이치 아스비오파마 가부시키가이샤 보조 펩타이드를 사용하는 펩타이드의 제조방법
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
EP1056413A4 (en) * 1998-02-27 2003-08-20 Bioelastics Res Ltd INJECTABLE IMPLANTS FOR TISSUE ENHANCEMENT AND RESTORATION
US6998387B1 (en) * 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
ES2138561B1 (es) 1998-04-17 2000-07-01 Univ Madrid Complutense Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos.
US20020151458A1 (en) 1998-04-17 2002-10-17 Perez Gomariz Rosa Maria Method for treating and preventing septic shock with VPAC1R, VPAC2R and PAC1R agonists
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
ES2553108T3 (es) 1998-08-10 2015-12-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diferenciación de células no productoras de insulina en células productoras de insulina mediante GLP-1 o exendina-4 y utilizaciones de las mismas
SG125915A1 (en) 1998-12-07 2006-10-30 Sod Conseils Rech Applic Analogues of glp-1
US6630438B1 (en) 1999-03-12 2003-10-07 The Procter & Gamble Company Perfumed detergent tablet
WO2000056774A1 (en) * 1999-03-19 2000-09-28 Duke University Methods of using bioelastomers
US20090175821A1 (en) 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6329336B1 (en) 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
CA2391448A1 (en) 1999-11-12 2001-05-17 Leo Rubin Use of vasoactive intestinal peptides and kits therefor
US6235264B1 (en) 1999-12-01 2001-05-22 General Electric Company Medical imaging method for characterizing tumor angiogenesis using polymeric contrast agents
US6593394B1 (en) 2000-01-03 2003-07-15 Prosperous Kingdom Limited Bioactive and osteoporotic bone cement
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
WO2001060862A1 (en) 2000-02-18 2001-08-23 Dabur Research Foundation Vasoactive intestinal peptide analogs
US20050255554A1 (en) 2000-03-20 2005-11-17 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
US6852834B2 (en) * 2000-03-20 2005-02-08 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
BR0111562A (pt) * 2000-06-16 2003-04-15 Lilly Co Eli Análogos de peptìdeo 1 semelhantes ao glucagon
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7176288B2 (en) 2000-09-13 2007-02-13 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US20020142964A1 (en) 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
CN1487952A (zh) 2000-11-28 2004-04-07 �ɶ����＼��ʵ���� 具有血管活性肠肽的生物学活性的用于治疗肺动脉和小动脉高压的化合物
DK1355942T3 (da) 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
US7259233B2 (en) * 2000-12-13 2007-08-21 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
WO2002066511A2 (en) 2001-02-16 2002-08-29 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
WO2002077218A1 (en) 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
US7235638B2 (en) 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
EP1542712A2 (en) * 2001-06-01 2005-06-22 Eli Lilly And Company Glp-1 formulations with protracted time action
US7101843B2 (en) * 2001-08-23 2006-09-05 Eli Lilly And Company Glucagon-like peptide-1 analogs
CN1635900A (zh) * 2001-08-28 2005-07-06 伊莱利利公司 Glp－1和基础胰岛素的预混合物
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US7179788B2 (en) * 2001-10-19 2007-02-20 Eli Lilly And Company Biphasic mixtures of GLP-1 and insulin
WO2003039577A1 (en) 2001-11-06 2003-05-15 Senju Pharmaceutical Co., Ltd. Remedies for dry eye and diseases associated with dry eye
DE10155862A1 (de) 2001-11-14 2003-05-28 Ipk Inst Fuer Pflanzengenetik Produktion von rekombinanten Antikörpern mittels Fusion mit Elastin-ähnlichen Peptiden
AU2002364586A1 (en) * 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US7553485B2 (en) 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US20030199445A1 (en) 2002-02-07 2003-10-23 Knudsen Lotte Bjerre Use of GLP-1 compound for treatment of critically ill patients
AU2003241531A1 (en) 2002-05-21 2003-12-12 Emory University Multivalent polymers with chain-terminating binding groups
CN1313149C (zh) 2002-06-10 2007-05-02 蒙杜生物科技安斯塔特实验室 具有血管活性肠肽的生物学活性的化合物在治疗结节病中的用途
WO2004020454A2 (en) 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
KR20050067439A (ko) 2002-11-27 2005-07-01 이토햄 가부시키가이샤 펩티드 및 이를 포함하는 의약조성물
US20050026826A1 (en) * 2003-01-17 2005-02-03 Margarethe Hoenig Feline proinsulin, insulin and constituent peptides
US20040234609A1 (en) * 2003-05-14 2004-11-25 Collier Katherine D. Repeat sequence protein polymer active agent congjugates, methods and uses
PL1633391T3 (pl) * 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
CA2528591C (en) 2003-06-12 2013-01-08 Eli Lilly And Company Glp-1 analog fusion proteins
US20040266993A1 (en) * 2003-06-30 2004-12-30 Evans Glen A. Non-immunoglobulin binding polypeptides
CA2532135A1 (en) 2003-07-14 2005-01-20 Mondobiotech Laboratories Anstalt Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung infections
WO2005014030A1 (en) 2003-07-24 2005-02-17 Lutz-Henning Block Method for treating lung diseases associated with ventilation-perfusion mismatches
WO2005074974A1 (en) 2004-02-05 2005-08-18 Novo Nordisk Health Care Ag Use of factor viia for treating late complications of trauma
US7776815B2 (en) 2004-02-24 2010-08-17 Wisconsin Alumni Research Foundation Use of neuropeptides for ligament healing
US7928059B2 (en) 2004-02-24 2011-04-19 Wisconsin Alumni Research Foundation Use of neuropeptides for traumatic cartilage injury
US20050203009A1 (en) 2004-03-12 2005-09-15 Bayer Pharmaceuticals Corporation VPAC1 selective antagonists and their pharmacological methods of use
WO2005097158A1 (en) 2004-03-29 2005-10-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Amphipathic glycopeptides
BRPI0511367B8 (pt) 2004-06-11 2021-05-25 Vectus Biosystems Ltd uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo
EP1768686A4 (en) 2004-06-12 2007-11-14 Bayer Pharmaceuticals Corp PEGYLATION OF VASOACTIVE INTESTINAL PEPTIDE (VIP) / HYPOPHYDE-ADENYLATE CYCLASE-ACTIVATING PEPTIDE (PACAP) RECEPTOR 2 (VPAC2) AGONISTS AND METHOD OF USE
WO2006001806A2 (en) 2004-06-15 2006-01-05 Duke University Method for non-invasive thermometry using elastin-like polypeptide conjugates
MX2007000728A (es) * 2004-07-21 2007-03-15 Ambrx Inc Polipeptidos biosinteticos que utilizan amino acidos no naturalmente codificados.
US20080085860A1 (en) 2004-08-18 2008-04-10 Eli Lilly And Company Selective Vpac2 Receptor Peptide Agonists
JP2008515437A (ja) 2004-10-08 2008-05-15 フォーブス メディ−テック（リサーチ） インコーポレーテッド 血管活性腸管ポリペプチド医薬品
SE0402976L (sv) * 2004-12-03 2006-06-04 Mederio Ag Medicinsk produkt
WO2006059939A1 (en) 2004-12-03 2006-06-08 Mederio Ag A medical product comprising a glucagon-like peptide medicament intended for pulmonary inhalation
WO2006078629A2 (en) 2005-01-18 2006-07-27 Duke University In-situ crosslinkable elastin-like polypeptides for defect filling in cartilaginous tissue repair
US7723472B2 (en) 2005-02-28 2010-05-25 The Regents Of The University Of California Extracellular matrix binding chimeric proteins and methods of use thereof
WO2006110292A2 (en) 2005-03-25 2006-10-19 The Regents Of The University Of California Temperature-triggered immobilization and purification of antibodies
US20090227493A1 (en) 2005-05-27 2009-09-10 Daiichi Sankyo Company, Limited Combined drug for treating diabetes
US20070031342A1 (en) 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
US20070009602A1 (en) 2005-06-24 2007-01-11 Setton Lori A Direct drug delivery system based on thermally responsive biopolymers
US20070041934A1 (en) 2005-08-12 2007-02-22 Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
US7542904B2 (en) * 2005-08-19 2009-06-02 Cisco Technology, Inc. System and method for maintaining a speech-recognition grammar
ES2397289T3 (es) * 2005-09-22 2013-03-06 Biocompatibles Uk Ltd. Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
BRPI0617740A2 (pt) 2005-10-26 2011-08-02 Lilly Co Eli agonistas seletivos peptìdicos do receptor vpac2, composição farmacêutica e uso dos referidos agonistas
US20100184651A1 (en) 2005-11-18 2010-07-22 Dabur Pharma Limited Targeted fusion proteins for cancer therapy
AU2006322656B2 (en) 2005-12-09 2012-03-08 Vectus Biosystems Limited VIP fragments and methods of use
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
EP1971355B1 (en) 2005-12-20 2020-03-11 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US7709227B2 (en) 2006-01-04 2010-05-04 Phasebio Pharmaceuticals, Inc. Multimeric ELP fusion constructs
AU2007221366B2 (en) * 2006-02-22 2012-08-23 Msd Italia S.R.L. Oxyntomodulin derivatives
EP1996937A4 (en) 2006-03-06 2009-04-08 Amunix Inc GENETIC PACKS AND USES THEREOF
ES2315081B1 (es) 2006-03-15 2009-12-30 Grup D'afectats D'esclerosi Multiple (Gaem) Nuevo uso del peptido intestinal vasoactivo (vip) y de las celulas aisladas estimuladas con dicho peptido.
EP2043689A4 (en) 2006-07-24 2013-08-07 Univ Duke ACTIVE ADMINISTRATION WITH STIMULUS-REPONSIVE BIOPOLYMERS
JP5256199B2 (ja) 2006-08-07 2013-08-07 テヴァ バイオファーマシューティカルズ ユーエスエー，インコーポレーティッド アルブミン−インスリン融合タンパク質
JP5290177B2 (ja) * 2006-08-31 2013-09-18 セントカー・インコーポレーテツド Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
CN103230598A (zh) 2006-09-06 2013-08-07 费斯生物制药公司 融合肽治疗组合物
CA2687602C (en) 2007-05-21 2014-07-15 Res International Sarl Peptides with improved properties having the biological activity of vasoactive intestinal peptide (vip) and their use for the treatment of lung diseases
AU2008262031B2 (en) 2007-06-08 2011-08-25 Boehringer Ingelheim International Gmbh Extended release formulation of nevirapine
DE602008005596D1 (de) 2007-06-21 2011-04-28 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
BRPI0815416A2 (pt) * 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
WO2009030738A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
JP2011503000A (ja) 2007-11-02 2011-01-27 セントコア・オーソ・バイオテツク・インコーポレーテツド 半合成ＧＬＰ−１ペプチド−Ｆｃ融合コンストラクト、その方法及び使用
US20110207673A1 (en) 2007-11-20 2011-08-25 Ashutosh Chilkoti Methods and compositions for modulating drug-polymer architecture, pharmacokinetics and biodistribution
JP2011526303A (ja) * 2008-06-27 2011-10-06 デューク ユニバーシティ エラスチン様ペプチドを含む治療剤
WO2010042997A1 (en) 2008-10-17 2010-04-22 Vectus Biosystems Pty Limited Compositions and methods for treatment of kidney disorders
US20110288001A1 (en) 2008-12-18 2011-11-24 Homayoun Sadeghi Biologically active proteins activatable by peptidase
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
MX366935B (es) 2009-08-14 2019-07-31 Phasebio Pharmaceuticals Inc Peptidos intestinales vasoactivos modificados.
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
US9561262B2 (en) 2011-06-06 2017-02-07 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
CA2846209C (en) 2011-08-24 2022-04-05 Phasebio Pharmaceuticals, Inc. Systemic sustained release formulation comprising elastin­like peptide repeating sequence and protein active agent
SG11201402661TA (en) 2011-11-28 2014-08-28 Phasebio Pharmaceuticals Inc Therapeutic agents comprising insulin amino acid sequences
US9605186B2 (en) 2012-09-19 2017-03-28 Exxonmobil Chemical Patents Inc. Adhesive compositions of ethylene-based and propylene-based polymers

Also Published As

Publication number Publication date
US20160120952A1 (en) 2016-05-05
WO2009158704A3 (en) 2010-03-18
US9127047B2 (en) 2015-09-08
US20200282022A1 (en) 2020-09-10
EP2307038A4 (en) 2013-03-27
US10596230B2 (en) 2020-03-24
US20190091297A1 (en) 2019-03-28
CN105727261A (zh) 2016-07-06
US11103558B2 (en) 2021-08-31
JP2019085420A (ja) 2019-06-06
HK1215182A1 (en) 2016-08-19
CN102131516A (zh) 2011-07-20
US20130079277A1 (en) 2013-03-28
WO2009158704A2 (en) 2009-12-30
EP4074327A1 (en) 2022-10-19
EP2926825A1 (en) 2015-10-07
JP2015218177A (ja) 2015-12-07
US20100022455A1 (en) 2010-01-28
US9200083B2 (en) 2015-12-01
EP3412300A1 (en) 2018-12-12
US20230000952A1 (en) 2023-01-05
CN102131516B (zh) 2016-03-16
US20160030521A1 (en) 2016-02-04
CA2953975C (en) 2019-11-26
US8178495B2 (en) 2012-05-15
JP2017088627A (ja) 2017-05-25
CA2953975A1 (en) 2009-12-30
US20130085104A1 (en) 2013-04-04
US9821036B2 (en) 2017-11-21
EP2307038A2 (en) 2011-04-13
US20130085099A1 (en) 2013-04-04
JP2011526303A (ja) 2011-10-06

Similar Documents

Publication Publication Date Title
CA2726894A1 (en) Therapeutic agents comprising elastin-like peptides
US10799565B2 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US8729018B2 (en) Therapeutic agents comprising elastic peptides
US10617741B2 (en) Compositions and methods for oral delivery of therapeutic cargo
AU2015349743B2 (en) ELP fusion proteins for controlled and sustained release
CN109310641A (zh) 用于受控和持续释放的elp融合蛋白
US20240207372A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140318

FZDE Discontinued

Effective date: 20180109